Member-only story
Small Biotech Company BioVie Inc. (BIVI) Hopes To Blast Off With Positive Data On Treating Alzheimer’s
The company's results on a recent study briefly pushed the stock’s share price soaring
With a market cap of around $87 million, biotech company BioVie Inc. (BIVI) is just a tadpole in a pool of frogs. However, they are hoping that will change in the near future, and the recent positive results they found during a Phase 2 trial of their NE3107 could be such a catalyst.
Based out of Beverly, Massachusetts, according to their website, BioVie:
“BioVie is a purpose-based company. Through innovation, collaboration, and people centered science, BioVie is creating new solutions enabling people to live healthier and better lives.”
They were founded in 2013 and are still in the early stages of establishing themselves in a very competitive market. Their financials are still floundering, although nothing unexpected for a clinical stage business of their age and position. There is significant cost with researching and developing treatments, not to mention marketing them if and when they prove viable.
BioVie works to identify therapies and treatments for diseases such as Parkinson’s, Ascites/Cirrhosis and Alzheimer’s. It is…
